Metabolic research
Tirzepatide review
A selected randomized obesity trial provides clinical evidence, with clear limits on what that evidence says about other products.
Peptide Index is operated by the team behind Peptide Guide, a peptide vendor. Read our disclosure.
Included evidence
Human phase 3 trial
What was studied
Adults with obesity or overweight and a weight-related complication, excluding diabetes, in the SURMOUNT-1 trial.
What the research found
- Tirzepatide produced greater weight reduction than placebo in the selected trial.
- Gastrointestinal adverse events were common; some participants discontinued treatment because of adverse events.
Where the evidence stops
- Results apply to the studied population and formulation, not every person or product sold under the same molecule name.
- This is a selected-study review, not a comparison with every available treatment.
Safety context
FDA distinguishes approved drugs from unapproved or compounded versions, which do not undergo the same premarket safety, effectiveness, and quality review.
Educational information only. This review does not recommend self-treatment or establish that products sold online match a studied formulation. Individual medical decisions belong with a qualified clinician.
Read the sources
These are the documents included in this review. Evidence labels describe this selection; they are not effectiveness or safety scores.
Original research — PubMed abstract
Tirzepatide Once Weekly for the Treatment of Obesity. (opens in a new tab)FDA safety information
FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (opens in a new tab)
This is a selected-source editorial review, not a systematic review or a claim of medical review. New findings may change the assessment.
Next editorial check due .
How these reviews are prepared